- Home
- WERN vs IRON Comparison
WERN vs IRON Comparison
Compare WERN & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WERN
- IRON
- Stock Information
- Founded
- WERN 1956
- IRON 2017
- Country
- WERN United States
- IRON United States
- Employees
- WERN N/A
- IRON N/A
- Industry
- WERN Trucking Freight/Courier Services
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- WERN Industrials
- IRON Health Care
- Exchange
- WERN Nasdaq
- IRON Nasdaq
- Market Cap
- WERN 1.8B
- IRON 1.4B
- IPO Year
- WERN N/A
- IRON N/A
- Fundamental
- Price
- WERN $25.97
- IRON $47.73
- Analyst Decision
- WERN Hold
- IRON Strong Buy
- Analyst Count
- WERN 12
- IRON 9
- Target Price
- WERN $31.50
- IRON $93.89
- AVG Volume (30 Days)
- WERN 923.5K
- IRON 356.0K
- Earning Date
- WERN 07-29-2025
- IRON 05-07-2025
- Dividend Yield
- WERN 2.16%
- IRON N/A
- EPS Growth
- WERN N/A
- IRON N/A
- EPS
- WERN 0.29
- IRON N/A
- Revenue
- WERN $2,973,292,000.00
- IRON N/A
- Revenue This Year
- WERN $0.52
- IRON N/A
- Revenue Next Year
- WERN $6.30
- IRON N/A
- P/E Ratio
- WERN $90.39
- IRON N/A
- Revenue Growth
- WERN N/A
- IRON N/A
- 52 Week Low
- WERN $23.02
- IRON $30.82
- 52 Week High
- WERN $42.48
- IRON $68.73
- Technical
- Relative Strength Index (RSI)
- WERN 41.82
- IRON 53.17
- Support Level
- WERN $25.86
- IRON $44.47
- Resistance Level
- WERN $26.68
- IRON $47.36
- Average True Range (ATR)
- WERN 0.60
- IRON 2.22
- MACD
- WERN -0.03
- IRON -0.06
- Stochastic Oscillator
- WERN 14.49
- IRON 55.44
About WERN Werner Enterprises Inc.
Werner Enterprises Inc is a transportation and logistics company. The company has two reportable segments - Truckload Transportation Services and Werner Logistics. It derives majority of its revenue from full-truckload transportation services and geographically from United States.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.